Not exact matches
According to the authors, the new findings provide a roadmap for future
clinical trials for
endometrial cancer.
Adding metformin to a combination of everolimus plus letrozole for women with advanced or recurrent endometrioid
endometrial cancer might offer
clinical benefits.
Potential cardioprotection was based on generally supportive data on lipid levels in intermediate outcome
clinical trials, trials in nonhuman primates, and a large body of observational studies suggesting a 40 % to 50 % reduction in risk among users of either estrogen alone or, less frequently, combined estrogen and progestin.2 - 5 Hip fracture was designated as a secondary outcome, supported by observational data as well as
clinical trials showing benefit for bone mineral density.6, 7 Invasive breast
cancer was designated as a primary adverse outcome based on observational data.3, 8 Additional
clinical outcomes chosen as secondary outcomes that may plausibly be affected by hormone therapy include other cardiovascular diseases;
endometrial, colorectal, and other
cancers; and other fractures.3, 6,9
Currently, the CDK9 inhibitor flavopiridol is being evaluated in several phase I and II
clinical trials for its anti-
cancer effects either as a single agent or in combination with other drugs in treatment of esophageal
cancer, B - cell chronic lymphocytic leukemia,
endometrial carcinoma, recurrent / metastatic squamous cell carcinoma and most relevantly, previously treated locally advanced or metastatic breast
cancer (http://www.cancernetwork.com/review-article/current-
clinical-trials-flavopiridol/page/0/2).
In fact, one comprehensive analysis of several
clinical trials found a reduced risk of bladder, breast, colorectal,
endometrial, gastric, lung, ovarian, pancreatic, prostate and renal
cancer.
In
clinical trials, Raloxifene (also used for osteoporosis) has been shown to cut the risk of breast
cancer by 70 percent without causing
endometrial cancer.